Monday, August 10, 2015

Public Health Organizations’ Positions on Medical Marijuana

Published by learnaboutsam

As the conversation about marijuana becomes more prevalent in the United State the SAFE Coalition feels it is important that you are aware of the viewpoints and stances of national organizations on the legalization of marijuana. 

American Society of Addiction Medicine: “ASAM asserts that cannabis, cannabis-based products and cannabis delivery devices should be subject to the same standards that are applicable to other prescription medications and medical devices, and that these products should not be distributed or otherwise provided to patients unless and until such products or devices have received marketing approval from the Food and Drug Administration. ASAM rejects smoking as a means of drug delivery since it is not safe. ASAM rejects a process whereby State and local ballot initiatives approve medicines because these initiatives are being decided by individuals not qualified to make such decisions.”

American Glaucoma Foundation: “Marijuana, or its components administered systemically, cannot be recommended without a long term trial which evaluates the health of the optic nerve. Although marijuana can lower IOP (Intraocular Pressure), its side effects and short duration of action, coupled with a lack of evidence that its use alters the course of glaucoma, preclude recommending this drug in any form for the treatment of glaucoma at the present time.”

National Multiple Sclerosis Society: “Although it is clear that cannabinoids have potential both for the management of MS symptoms, such as pain and spasticity, as well as for neuroprotection, the Society cannot at this time recommend that medical marijuana be made widely available to people with MS for symptom management. This decision was not only based on existing legal barriers to its use but, even more importantly, because studies to date do not demonstrate a clear benefit compared to existing symptomatic therapies and because issues of side effects, systemic effects, and long-term effects are not yet clear.” — Recommendations Regarding the Use of Cannabis in Multiple Sclerosis: Executive Summary. National Clinical Advisory Board of the National Multiple Sclerosis Society, Expert Opinion Paper, Treatment Recommendations for Physicians, April 2, 2008.

The American Academy of Pediatrics (AAP) believes that “[a]ny change in the legal status of marijuana, even if limited to adults, could affect the prevalence of use among adolescents.” While it supports scientific research on the possible medical use of cannabinoids as opposed to smoked marijuana, it opposes the legalization of marijuana. — Committee on Substance Abuse and Committee on Adolescence. “Legalization of Marijuana: Potential Impact on Youth.” Pediatrics Vol. 113, No. 6 (June 6, 2004): 1825-1826. See also, Joffe, Alain, MD, MPH, and Yancy, Samuel, MD. “Legalization of Marijuana: Potential Impact on Youth.” Pediatrics Vol. 113, No. 6 (June 6, 2004): e632-e638h.

Similarly, Dr. Christian Thurstone, a psychiatrist board-certified in general, child and adolescent and addictions psychiatry, who serves as an associate professor of psychiatry at the University of Colorado and as medical director of one of Colorado’s largest adolescent substance-abuse-treatment programs, said: “In the absence of credible data, this debate is being dominated by bad science and misinformation from people interested in using medical marijuana as a step to legalization for recreational use. Bypassing the FDA’s well-established approval process has created a mess that especially affects children and adolescents. Young people, who are clearly being targeted with medical marijuana advertising and diversion, are most vulnerable to developing marijuana addiction and suffering from its lasting effects.”

For more information on marijuana in the state of Iowa please contact the Van Buren County SAFE Coalition at 319-293-6412 or by email at  You may also check the following sites for up to date information:,,, and

No comments: